{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:06:18Z","timestamp":1776747978003,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/DTP\/0076\/POCI-01-0145-FEDER-006868"],"award-info":[{"award-number":["UID\/DTP\/0076\/POCI-01-0145-FEDER-006868"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["10.544999\/SFRH\/BD\/143717\/2019"],"award-info":[{"award-number":["10.544999\/SFRH\/BD\/143717\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/00776\/2020"],"award-info":[{"award-number":["UIDP\/00776\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CEECINST\/00091\/2018"],"award-info":[{"award-number":["CEECINST\/00091\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011776","name":"Instituto Portugu\u00eas de Oncologia do Porto","doi-asserted-by":"publisher","award":["CI\u2010IPOP\/PD\/Kymab"],"award-info":[{"award-number":["CI\u2010IPOP\/PD\/Kymab"]}],"id":[{"id":"10.13039\/501100011776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011776","name":"Instituto Portugu\u00eas de Oncologia do Porto","doi-asserted-by":"publisher","award":["BF.CBEG CI-IPOP- 27-2016"],"award-info":[{"award-number":["BF.CBEG CI-IPOP- 27-2016"]}],"id":[{"id":"10.13039\/501100011776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-024-01700-3","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T06:02:01Z","timestamp":1722664921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines"],"prefix":"10.1186","volume":"16","author":[{"given":"Nair","family":"Lopes","sequence":"first","affiliation":[]},{"given":"Sofia","family":"Salta","sequence":"additional","affiliation":[]},{"given":"Bianca Troncarelli","family":"Flores","sequence":"additional","affiliation":[]},{"given":"Vera","family":"Miranda-Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Margareta P.","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Gigliano","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Guimar\u00e3es","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"issue":"3","key":"1700_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163(3):649-58.e2.","journal-title":"Gastroenterology"},{"issue":"8","key":"1700_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941\u201353.","journal-title":"Int J Cancer"},{"key":"1700_CR3","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169-75","DOI":"10.1038\/nature20805"},{"issue":"26","key":"1700_CR4","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMra1314530","volume":"371","author":"AK Rustgi","year":"2014","unstructured":"Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499\u2013509.","journal-title":"N Engl J Med"},{"key":"1700_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.semcancer.2020.07.015","volume":"83","author":"ME Neganova","year":"2022","unstructured":"Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Semin Cancer Biol. 2022;83:452\u201371.","journal-title":"Semin Cancer Biol"},{"issue":"37","key":"1700_CR6","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420\u201332.","journal-title":"Oncogene"},{"issue":"7","key":"1700_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7150\/ijbs.9067","volume":"10","author":"Z Li","year":"2014","unstructured":"Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci. 2014;10(7):757\u201370.","journal-title":"Int J Biol Sci"},{"key":"1700_CR8","doi-asserted-by":"publisher","first-page":"175216","DOI":"10.1016\/j.ejphar.2022.175216","volume":"931","author":"R Hai","year":"2022","unstructured":"Hai R, Yang D, Zheng F, Wang W, Han X, Bode AM, et al. The emerging roles of HDACs and their therapeutic implications in cancer. Eur J Pharmacol. 2022;931:175216.","journal-title":"Eur J Pharmacol"},{"issue":"24","key":"1700_CR9","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1021\/jm0303094","volume":"46","author":"TA Miller","year":"2003","unstructured":"Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem. 2003;46(24):5097\u2013116.","journal-title":"J Med Chem"},{"issue":"11","key":"1700_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195\u2013206.","journal-title":"Lancet Oncol"},{"issue":"(Spec Feature)","key":"1700_CR11","first-page":"84","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA. Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma. Am Health Drug Benefits. 2016;9((Spec Feature)):84\u20137.","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"1700_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1186\/s12885-021-08579-w","volume":"21","author":"AC Harttrampf","year":"2021","unstructured":"Harttrampf AC, da Costa MEM, Renoult A, Daudigeos-Dubus E, Geoerger B. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation. BMC Cancer. 2021;21(1):833.","journal-title":"BMC Cancer"},{"issue":"7","key":"1700_CR13","doi-asserted-by":"publisher","first-page":"e0271245","DOI":"10.1371\/journal.pone.0271245","volume":"17","author":"Y Hazama","year":"2022","unstructured":"Hazama Y, Tsujioka T, Kitanaka A, Tohyama K, Shimoya K. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines. PLoS ONE. 2022;17(7):e0271245.","journal-title":"PLoS ONE"},{"issue":"2","key":"1700_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/cei\/uxac068","volume":"209","author":"X Lu","year":"2022","unstructured":"Lu X, Liu M, Yang J, Que Y, Zhang X. Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma. Clin Exp Immunol. 2022;209(2):127\u201339.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"1700_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.neo.2021.04.003","volume":"23","author":"M Ovejero-S\u00e1nchez","year":"2021","unstructured":"Ovejero-S\u00e1nchez M, Gonz\u00e1lez-Sarmiento R, Herrero AB. Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair. Neoplasia. 2021;23(5):515\u201328.","journal-title":"Neoplasia"},{"key":"1700_CR16","doi-asserted-by":"crossref","unstructured":"Wu K, Zhang H, Zhou L, Chen L, Mo C, Xu S, et al. Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer. Exp Cell Res. 2022. 113362.","DOI":"10.1016\/j.yexcr.2022.113362"},{"issue":"15","key":"1700_CR17","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1158\/1078-0432.CCR-20-2357","volume":"27","author":"L Xiao","year":"2021","unstructured":"Xiao L, Somers K, Murray J, Pandher R, Karsa M, Ronca E, et al. Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma. Clin Cancer Res. 2021;27(15):4338\u201352.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1700_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/cbf.3359","volume":"36","author":"YW Cheng","year":"2018","unstructured":"Cheng YW, Liao LD, Yang Q, Chen Y, Nie PJ, Zhang XJ, et al. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cell Biochem Funct. 2018;36(8):398\u2013407.","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"1700_CR19","doi-asserted-by":"publisher","first-page":"100789","DOI":"10.1016\/j.esmoop.2023.100789","volume":"8","author":"HC Puhr","year":"2023","unstructured":"Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789.","journal-title":"ESMO Open"},{"key":"1700_CR20","doi-asserted-by":"crossref","unstructured":"Sheikh M, Roshandel G, McCormack V, Malekzadeh R. Current Status and Future Prospects for Esophageal Cancer. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030765"},{"key":"1700_CR21","doi-asserted-by":"crossref","unstructured":"Pacheco MB, Camilo V, Lopes N, Moreira-Silva F, Correia MP, Henrique R, et al. Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals (Basel). 2021;14(7).","DOI":"10.3390\/ph14070670"},{"key":"1700_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cellsig.2019.03.014","volume":"59","author":"G Qin","year":"2019","unstructured":"Qin G, Li Y, Xu X, Wang X, Zhang K, Tang Y, et al. Panobinostat (LBH589) inhibits Wnt\/\u03b2-catenin signaling pathway via upregulating APCL expression in breast cancer. Cell Signal. 2019;59:62\u201375.","journal-title":"Cell Signal"},{"issue":"6","key":"1700_CR23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3892\/mco.2014.349","volume":"2","author":"A Sato","year":"2014","unstructured":"Sato A, Asano T, Isono M, Ito K, Asano T. Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth. Mol Clin Oncol. 2014;2(6):1016\u201322.","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"1700_CR24","doi-asserted-by":"publisher","first-page":"e0158208","DOI":"10.1371\/journal.pone.0158208","volume":"11","author":"\u00d8 Helland","year":"2016","unstructured":"Helland \u00d8, Popa M, Bischof K, Gjertsen BT, McCormack E, Bj\u00f8rge L. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLoS ONE. 2016;11(6):e0158208.","journal-title":"PLoS ONE"},{"issue":"3","key":"1700_CR25","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/bcr3192","volume":"14","author":"CR Tate","year":"2012","unstructured":"Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"1700_CR26","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-10-2430","volume":"71","author":"MJ LaBonte","year":"2011","unstructured":"LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, et al. The dual EGFR\/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011;71(10):3635\u201348.","journal-title":"Cancer Res"},{"issue":"4","key":"1700_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s10637-012-9914-7","volume":"31","author":"PM Wilson","year":"2013","unstructured":"Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, et al. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs. 2013;31(4):845\u201357.","journal-title":"Invest New Drugs"},{"issue":"3","key":"1700_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ijc.26057","volume":"130","author":"MG Catalano","year":"2012","unstructured":"Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer. 2012;130(3):694\u2013704.","journal-title":"Int J Cancer"},{"key":"1700_CR29","doi-asserted-by":"crossref","unstructured":"Lobo J, Guimar\u00e3es-Teixeira C, Barros-Silva D, Miranda-Gon\u00e7alves V, Camilo V, Guimar\u00e3es R, et al. Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. Cancers (Basel). 2020;12(10).","DOI":"10.3390\/cancers12102903"},{"issue":"2","key":"1700_CR30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","volume":"18","author":"S Landreville","year":"2012","unstructured":"Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18(2):408\u201316.","journal-title":"Clin Cancer Res"},{"key":"1700_CR31","doi-asserted-by":"publisher","first-page":"459052","DOI":"10.1155\/2015\/459052","volume":"2015","author":"L Gao","year":"2015","unstructured":"Gao L, Gao M, Yang G, Tao Y, Kong Y, Yang R, et al. Synergistic activity of carfilzomib and panobinostat in multiple myeloma cells via modulation of ROS generation and ERK1\/2. Biomed Res Int. 2015;2015:459052.","journal-title":"Biomed Res Int"},{"issue":"1","key":"1700_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1476-4598-12-114","volume":"12","author":"X Song","year":"2013","unstructured":"Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, et al. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin\/STAT3\/Akt pathway. Mol Cancer. 2013;12(1):114.","journal-title":"Mol Cancer"},{"key":"1700_CR33","doi-asserted-by":"crossref","unstructured":"Lee NR, Kim DY, Jin H, Meng R, Chae OH, Kim SH, et al. 2021 Inactivation of the Akt\/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells. Int J Mol Sci 22(11).","DOI":"10.3390\/ijms22115955"},{"issue":"1","key":"1700_CR34","first-page":"283","volume":"56","author":"J De La Rosa","year":"2020","unstructured":"De La Rosa J, Urdiciain A, Zazpe I, Zelaya MV, Mel\u00e9ndez B, Rey JA, et al. The synergistic effect of DZ-NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. Int J Oncol. 2020;56(1):283\u2013300.","journal-title":"Int J Oncol"},{"issue":"2","key":"1700_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"N Khan","year":"2008","unstructured":"Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581\u20139.","journal-title":"Biochem J"},{"issue":"12","key":"1700_CR36","doi-asserted-by":"publisher","first-page":"22400","DOI":"10.1002\/jcp.28805","volume":"234","author":"S Ma","year":"2019","unstructured":"Ma S, Liu T, Xu L, Wang Y, Zhou J, Huang T, et al. Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K\/Akt\/mTOR pathway. J Cell Physiol. 2019;234(12):22400\u201310.","journal-title":"J Cell Physiol"},{"issue":"7","key":"1700_CR37","doi-asserted-by":"publisher","first-page":"E1150","DOI":"10.1210\/jc.2011-2970","volume":"97","author":"MG Catalano","year":"2012","unstructured":"Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, Poli R, et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 2012;97(7):E1150\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1700_CR38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3892\/ijo.2013.2218","volume":"44","author":"N Fortunati","year":"2014","unstructured":"Fortunati N, Marano F, Bandino A, Frairia R, Catalano MG, Boccuzzi G. The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. Int J Oncol. 2014;44(3):700\u20138.","journal-title":"Int J Oncol"},{"issue":"3","key":"1700_CR39","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10549-014-2979-6","volume":"145","author":"LV Rhodes","year":"2014","unstructured":"Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014;145(3):593\u2013604.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1700_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/mc.22117","volume":"54","author":"S Junqueira-Neto","year":"2015","unstructured":"Junqueira-Neto S, Vieira FQ, Montezuma D, Costa NR, Antunes L, Baptista T, et al. Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder. Mol Carcinog. 2015;54(7):523\u201331.","journal-title":"Mol Carcinog"},{"key":"1700_CR41","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.2147\/DDDT.S211665","volume":"13","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yuan T, Zhang Y, Shi J, Bai L, Duan X, et al. AR-42: a pan-HDAC inhibitor with antitumor and antiangiogenic activities in esophageal squamous cell carcinoma. Drug Des Devel Ther. 2019;13:4321\u201330.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"1700_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s10637-018-0651-4","volume":"37","author":"L Zhong","year":"2019","unstructured":"Zhong L, Zhou S, Tong R, Shi J, Bai L, Zhu Y, et al. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Invest New Drugs. 2019;37(4):616\u201324.","journal-title":"Invest New Drugs"},{"issue":"4","key":"1700_CR43","first-page":"769","volume":"18","author":"M Nakagawa","year":"2007","unstructured":"Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 2007;18(4):769\u201374.","journal-title":"Oncol Rep"},{"issue":"2","key":"1700_CR44","first-page":"333","volume":"10","author":"Y Toh","year":"2003","unstructured":"Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep. 2003;10(2):333\u20138.","journal-title":"Oncol Rep"},{"issue":"11","key":"1700_CR45","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/jcp.2010.080952","volume":"63","author":"R Langer","year":"2010","unstructured":"Langer R, Mutze K, Becker K, Feith M, Ott K, Hofler H, et al. Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. J Clin Pathol. 2010;63(11):994\u20138.","journal-title":"J Clin Pathol"},{"issue":"1","key":"1700_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12935-022-02581-3","volume":"22","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhang Y, Lin Z, Wu K, He Z, Zhu D, et al. Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1. Cancer Cell Int. 2022;22(1):191.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"1700_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/15592294.2015.1039216","volume":"10","author":"TD Ahrens","year":"2015","unstructured":"Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, et al. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and azacytidine. Epigenetics. 2015;10(5):431\u201345.","journal-title":"Epigenetics"},{"issue":"1","key":"1700_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41420-023-01399-w","volume":"9","author":"R He","year":"2023","unstructured":"He R, Liu B, Geng B, Li N, Geng Q. The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases. Cell Death Discov. 2023;9(1):131.","journal-title":"Cell Death Discov"},{"issue":"21","key":"1700_CR49","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","volume":"63","author":"TCS Ho","year":"2020","unstructured":"Ho TCS, Chan AHY, Ganesan A. Thirty years of hdac inhibitors: 2020 insight and hindsight. J Med Chem. 2020;63(21):12460\u201384.","journal-title":"J Med Chem"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-024-01700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-024-01700-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-024-01700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T18:02:26Z","timestamp":1722708146000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-024-01700-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1186\/s13148-024-01700-3","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Institutional Review Board (Comiss\u00e3o de \u00c9tica para a Sa\u00fade) of IPO Porto (CES 202\/017). All the procedures involving the use of human samples were in accordance with the national ethical standards and following the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}